Active Not Recruiting PHASE2 INTERVENTIONAL 1-arm NCT06599216

Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR + / HER2- Breast Cancer

Adebrelimab Combined With Dalpicicliband Standard Endocrine Therapy for HR + / HER 2-breast Cancer:A Single-center,Open-label,Single-arm Clinical Trial

Sponsor: Harbin Medical University

Conditions Breast Cancer HR+/HER2- Breast Cancer

Interventions Adebrelimab+Dalpciclib+Standard Endocrine Therapy

Updated 3 times since 2024 Last updated: Aug 19, 2025 Started: Oct 8, 2024 Primary completion: Mar 1, 2026 Completion: Sep 1, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06599216, this PHASE2 trial focuses on Breast Cancer and HR+/HER2- Breast Cancer and remains ongoing. Sponsored by Harbin Medical University, it has been updated 3 times since 2024, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

3 versions recorded

Sep 2025 — Present [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Apr 2025 — Sep 2025 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Oct 2024 — Apr 2025 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Harbin Medical University

Data source: Harbin Medical University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Harbin, China